Claims for Patent: 8,647,627

Summary for Patent: 8,647,627

Title:	Composition for a cancer vaccine
Abstract:	Pharmaceutical compositions useful as vaccines are described containing a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer, at least one interleukin (IL), and at least one colony stimulating factor (CSF), where the purified surface or excreted protein is provided in an amount sufficient to induce an immune response in an individual administered the composition. Such compositions can be used in methods for treating individuals having cancer, and for inducing an immunotherapeutic response in the same.
Inventor(s):	Head; Jonathan F. (Baton Rouge, LA), Elliott; Robert L. (Baton Rouge, LA)
Assignee:	OncBioMune, L.L.C. (Baton Rouge, LA)
Application Number:	13/005,993
Patent Claims:	1. A composition consisting of a pharmaceutically acceptable carrier and about 50 .mu.g PSA, about 2 .mu.g CEA, about 1000 IU CA 125, about 20,000 units IL-2, and about 16.7 .mu.g GM-CSF, per dose of the composition. 2. The composition of claim 1, wherein pharmaceutically acceptable carrier comprises a physiologically acceptable aqueous buffer or solution. 3. The composition of claim 2, wherein pharmaceutically acceptable carrier comprises sterile water, saline, phosphate-buffered saline, or Hank's buffered salt solution (HBSS).

Details for Patent 8,647,627

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-22